Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
NCT06992440
Recruiting
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
NCT06826612
Recruiting
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
07/02/2025
Locations: University of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Huntington Disease
Register for Updates
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
NCT06708299
Recruiting
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 14 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients who discontinue therapy with an IL-1 blocke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Recurrent Pericarditis
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/02/2025
Locations: Clinical Site, Cincinnati, Ohio
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
NCT06630221
Recruiting
The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML. Eltrombopag is a Food and Drug Administration (FDA) approved drug fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio
Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
NCT06544564
Recruiting
This study is designed to assess the clinical effectiveness of Membrane Wrap, a human amniotic membrane for the management of difficult to heal partial- or full-thickness venous leg ulcers (VLUs)
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
07/02/2025
Locations: Kent State College of Podiatry, Cleveland, Ohio
Conditions: Venous Leg Ulcer
Register for Updates
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031
Recruiting
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/02/2025
Locations: The Christ Hospital - Cincinnati, Cincinnati, Ohio
Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure
Register for Updates
CLEANer Aspiration for Pulmonary Embolism
NCT06189313
Recruiting
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Register for Updates
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
NCT06139627
Recruiting
This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical co... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/02/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Register for Updates
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
NCT06131801
Recruiting
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More
Gender:
ALL
Ages:
Between 0 years and 38 years
Trial Updated:
07/02/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
Register for Updates
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT06026657
Recruiting
This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. TGFBi NK cells are manufact... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Register for Updates
Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
NCT05984888
Recruiting
Breast cancer (BC) is the most frequently diagnosed cancer in women. Systemic cancer treatments are an important contributor to dramatic improvements in the long-term survival of women with BC. However, cancer treatment can lead to cognitive impairment and declines in quality of life in women with BC. Many cancer survivors experience memory and brain function decline following chemotherapy which can last for years. A newer diet pattern, Mediterranean-DASH \[Dietary Approaches to Stop Hypertensio... Read More
Gender:
FEMALE
Ages:
Between 45 years and 75 years
Trial Updated:
07/02/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates